Sandoz's New Leadership: Francisco Ballester Retires, Peter Stenico Appointed President Region International

Sandoz, the global leader in generic and biosimilar medicines, announced a significant leadership change on February 3, 2025. Francisco Ballester, President Region International and member of the Sandoz Executive Committee, will retire and step down from the SEC on March 1, 2025. Since 2019, Ballester has been responsible for driving business growth and access for patients in markets outside of North America and Europe, while developing highly diverse talents in the region. He is a member of the Health Management and Policy Advisory Council of the Miami Herbert Business School.

Drawing on a strong bench of internal leaders, Peter Stenico will succeed Ballester. Stenico was appointed Global Platform Head, Biosimilars in January 2023 and has led Sandoz's global biosimilar strategy. Previously, he held the position of Country Head and General Manager for Sandoz in Germany and was also the former President of the German Generics Association (Pro Generika). Stenico joined Sandoz in 2002 and has gained vast biosimilars and generics industry experience through various roles covering strategy, M&A, and commercial at global, regional, and local levels.

Richard Saynor, Chief Executive Officer of Sandoz, said: "It is not every day we can recognize a colleague who has devoted virtually his entire career to our company. Francisco spent over three decades taking on diverse and increasingly more senior roles at the organization, demonstrating focus, passion, and dedication to the business and our people. I am personally grateful for his many contributions and insights we have worked together on the Sandoz Executive Committee. I wish Francisco all the very best for his retirement.

I am immensely proud of the huge wealth of experience we have at Sandoz. Like Francisco, Peter can look back on a successful career of many decades at Sandoz and he will bring this extensive experience to his new role and to the Sandoz Executive Committee. I welcome him to the team and wish him much success in taking Sandoz Region International to the next level of growth."

The transition from Ballester to Stenico is expected to have a significant impact on Sandoz's global biosimilar strategy and market position. Stenico's extensive experience in the biosimilars and generics industry, along with his leadership in Sandoz's global biosimilar strategy, will be crucial in driving the company's biosimilar efforts forward and taking the company to the next level of growth.

In addition, Stenico's appointment as President Region International and a member of the Sandoz Executive Committee further solidifies his position as a key player in the company's biosimilar efforts. His leadership in this role will be crucial in driving Sandoz's biosimilar strategy forward and taking the company to the next level of growth.

Overall, the transition from Francisco Ballester to Peter Stenico is expected to have a positive impact on Sandoz's global biosimilar strategy and market position, as Stenico's extensive experience and commitment to the company's biosimilar efforts will help to drive the company's success in this important market segment.